Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | BDKRB2 | P30411 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 4/20 | 0.39 |
| ▸ | CASP7 | P55210 | 3/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CCR4 | P51679 | 4/20 | 0.39 |
| ▸ | ECE1 | P42892 | 3/20 | 0.39 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7844033 | 1.00 | MMP9 (0.50) | MMP9BDKRB2LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL7846611 | 0.87 | MMP9 (0.52) | MMP9BDKRB2LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL6946762 | 0.87 | MMP9 (0.52) | MMP9BDKRB2LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL5414263 | 0.85 | MMP9 (0.41) | MMP9BDKRB2LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL5414258 | 0.85 | MMP9 (0.41) | MMP9BDKRB2LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL6951034 | 0.85 | MMP9 (0.53) | MMP9BDKRB2ALDH1A1CCR4ECE1 | |
| SCHEMBL6945270 | 0.85 | MMP9 (0.53) | MMP9BDKRB2ALDH1A1CCR4ECE1 | |
| SCHEMBL5415738 | 0.80 | MMP9 (0.41) | MMP9BDKRB2LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL5401022 | 0.80 | MMP9 (0.44) | MMP9BDKRB2LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL5405167 | 0.80 | CASP3 (0.45) | LMNAALDH1A1SMN1; SMN2CASP3CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1147107-A4 | NOVEL ANGIOGENESIS INHIBITORS | MERCK & CO INC (US) | 2002-05-22 | — | — | EP | claimed |
| EP-1147107-A1 | NOVEL ANGIOGENESIS INHIBITORS | Merck & Co., Inc. (US) | 2001-10-24 | — | — | EP | claimed |
| WO-2000043393-A1 | NOVEL ANGIOGENESIS INHIBITORS | MERCK & CO., INC. (US) | 2000-07-27 | — | — | WO | claimed |
| US-6610882-B2 | Affinity for bradykinin receptors; antithrombotics | SANOFI-SYNTHELABO (FR) | 2003-08-26 | — | — | US | disclosed |
| US-20030073641-A1 | Novel N-(arylsulphonyl) amino acid derivatives, process for their preparation and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2003-04-17 | — | — | US | disclosed |
| US-20020115685-A1 | Novel N-(arylsulphonyl) amino acid derivatives, process for their preparation and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2002-08-22 | — | — | US | disclosed |
| US-6433185-B1 | ANTIINFLAMMATORY AGENTS; ANALGESICS | SANOFI-SYNTHELABO (FR) | 2002-08-13 | — | — | US | disclosed |
| EP-1147107-A4 | NOVEL ANGIOGENESIS INHIBITORS | MERCK & CO INC (US) | 2002-05-22 | — | — | EP | disclosed |
| US-6313120-B1 | TREATMENT OR PREVENTION OF DISEASES INVOLVING BRADYKININ RECEPTORS | SANOFI-SYNTHELABO (FR) | 2001-11-06 | — | — | US | disclosed |
| EP-1147107-A1 | NOVEL ANGIOGENESIS INHIBITORS | Merck & Co., Inc. (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6100278-A | COMPOUNDS HAVING AFFINITY FOR BRADYKININ RECEPTORS; ANTIINFLAMMATORY AGENTS | SANOFI-SYNTHELABO (FR) | 2000-08-08 | — | — | US | disclosed |
| WO-2000043393-A1 | NOVEL ANGIOGENESIS INHIBITORS | MERCK & CO., INC. (US) | 2000-07-27 | — | — | WO | disclosed |
| US-6015812-A | N-(arylsulphonyl)amino acid derivatives having bradykinin receptor affinity | SANOFI-SYNTHELABO (FR) | 2000-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115685-A1 | Novel N-(arylsulphonyl) amino acid derivatives, process for their preparation and pharmaceutical compositions containing them | CYP2C9, ADRM1, ADRA1D | MMP9 3790/4885BDKRB2 1658/4885LMNA 3733/4885 |
| US-20030073641-A1 | Novel N-(arylsulphonyl) amino acid derivatives, process for their preparation and pharmaceutical compositions containing them | CYP2C9, ADRM1, ADRA1D | MMP9 3790/4885BDKRB2 1658/4885LMNA 3733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.